Inovio Pharmaceuticals, Inc.
INO- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001055726
No open-market purchases or sales by Inovio Pharmaceuticals, Inc. insiders were filed in the last 90 days; 101 institutions reported holding it in 13F filings for Q2 2026, worth $36.1M in total; no superinvestor holds it.
13F holders, Q3 2025
Institutional positions in Inovio Pharmaceuticals, Inc. as of Sep 30, 2025. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 99
- −4 vs. Q2 2025
- Shares held
- 20.7M
- +10.5M (+103.7%) vs. Q2 2025
- Total value
- $48.4M
- +$27.8M (+134.1%) vs. Q2 2025
- New holders
- 24
- 22 more added
- Sold out
- 28
- 27 more reduced
Compare with Q2 2025: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting INO on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 101 | $36.1M |
| Q1 2026 | 99 | $54.6M |
| Q4 2025 | 101 | $57.5M |
| Q3 2025 | 99 | $48.4M |
| Q2 2025 | 103 | $20.7M |
| Q1 2025 | 108 | $22.2M |
| Q4 2024 | 105 | $24.4M |
| Q3 2024 | 98 | $49.5M |
| Q2 2024 | 96 | $65.1M |
| Q1 2024 | 89 | $56.4M |
| Q4 2023 | 116 | $25.7M |
| Q3 2023 | 127 | $21.6M |
| Q2 2023 | 135 | $32.1M |
| Q1 2023 | 177 | $99.8M |
| Q4 2022 | 186 | $198.5M |
| Q3 2022 | 183 | $200.0M |
| Q2 2022 | 185 | $196.2M |
| Q1 2022 | 201 | $330.4M |
| Q4 2021 | 209 | $428.9M |
| Q3 2021 | 213 | $554.9M |
| Q2 2021 | 211 | $683.1M |
| Q1 2021 | 219 | $693.7M |
Institutions, Q3 2025
Shares, value and share of portfolio for each institution holding Inovio Pharmaceuticals, Inc.; share changes are against Q2 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Cubist Systematic Strategies, LLC | 0 | $0 | 0.00% | −171,561−100.0% | Sold out |
| AQR Capital Management LLC | 0 | $0 | 0.00% | −53,171−100.0% | Sold out |
| American Century Companies Inc | 0 | $0 | 0.00% | −42,917−100.0% | Sold out |
| Y-Intercept (Hong Kong) Ltd | 0 | $0 | 0.00% | −42,171−100.0% | Sold out |
| Virtu Financial LLC | 0 | $0 | 0.00% | −38,482−100.0% | Sold out |
| Jain Global LLC | 0 | $0 | 0.00% | −37,601−100.0% | Sold out |
| Squarepoint Ops LLC | 0 | $0 | 0.00% | −32,572−100.0% | Sold out |
| HSBC Holdings PLC | 0 | $0 | 0.00% | −26,075−100.0% | Sold out |
| Two Sigma Securities, LLC | 0 | $0 | 0.00% | −23,003−100.0% | Sold out |
| Nomura Holdings Inc | 0 | $0 | 0.00% | −20,987−100.0% | Sold out |
| Boothbay Fund Management, LLC | 0 | $0 | 0.00% | −18,000−100.0% | Sold out |
| Point72 Asia (Singapore) Pte. Ltd. | 0 | $0 | 0.00% | −17,886−100.0% | Sold out |
| Catalyst Funds Management Pty Ltd | 0 | $0 | 0.00% | −17,000−100.0% | Sold out |
| Eqis Capital Management, Inc. | 0 | $0 | 0.00% | −16,387−100.0% | Sold out |
| Tower Research Capital LLC (TRC) | 0 | $0 | 0.00% | −11,687−100.0% | Sold out |
| Keystone Financial Group | 0 | $0 | 0.00% | −10,073−100.0% | Sold out |
| CWM, LLC | 0 | $0 | 0.00% | −5,532−100.0% | Sold out |
| Point72 (DIFC) Ltd | 0 | $0 | 0.00% | −2,600−100.0% | Sold out |
| Russell Investments Group, Ltd. | 0 | $0 | 0.00% | −2,070−100.0% | Sold out |
| Nisa Investment Advisors, LLC | 0 | $0 | 0.00% | −361−100.0% | Sold out |
| American National Bank | 0 | $0 | 0.00% | −200−100.0% | Sold out |
| US Bancorp | 0 | $0 | 0.00% | −62−100.0% | Sold out |
| EverSource Wealth Advisors, LLC | 0 | $0 | 0.00% | −40−100.0% | Sold out |
| True Wealth Design, LLC | 0 | $0 | 0.00% | −15−100.0% | Sold out |
| Larson Financial Group LLC | 0 | $0 | 0.00% | −8−100.0% | Sold out |
| S&T Bank | 0 | $0 | 0.00% | −4−100.0% | Sold out |
| Ameritas Advisory Services, LLC | 0 | $0 | 0.00% | −2−100.0% | Sold out |